Reuters
22 Sept 2026, 11:40 UTC · 1h ago
Verdict
Headline takes no side. We score CLDX +1.00 across one claim — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Celldex Therapeutics announced on Tuesday that its experimental skin disease drug met primary and secondary goals in two late-stage trials.
Newsaid on Tuesday
So whatSuccess in two late-stage trials significantly increases the probability of FDA filing and approval within the next 12-24 months.
More positive than 99% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 98% of ticker scores this week
Experimental drug met both main and secondary goals in two late-stage trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
7h ago
—
CLDX hasn't traded since this ran. Last close $37.89 (Sep 21); the reaction starts at the next open.
CLDX chart →